Detailed studies of apolipoprotein E (apoE)-containing lipoproteins in abetalipoproteinemia have been performed in an attempt to resolve the apparent paradox of a suppressed low density lipoprotein (LDL) receptor pathway in the absence of apoB-containing lipoproteins. It was hypothesized that apoE-containing high density lipoproteins (HDL) in abetalipoproteinemia might functionally substitute for LDL in regulation of cholesterol metabolism in these patients.
A B S T R A C T Detailed studies of apolipoprotein E (apoE)-containing lipoproteins in abetalipoproteinemia have been performed in an attempt to resolve the apparent paradox of a suppressed low density lipoprotein (LDL) receptor pathway in the absence of apoB-containing lipoproteins. It was hypothesized that apoE-containing high density lipoproteins (HDL) in abetalipoproteinemia might functionally substitute for LDL in regulation of cholesterol metabolism in these patients.
The mean (±standard deviation) plasma concentration of apoE in nine patients with abetalipoproteinemia was 44.8±8.2 ug/ml, slightly higher than the corresponding value for a group of 50 normal volunteers, 36.3±11 gg/ml. Fractionation of plasma lipoproteins by agarose column chromatography or by ultracentrifugation indicated that in abetalipoproteinemia, plasma apoE was restricted to a subfraction of HDL. This was in contrast to the results obtained with plasma from 30 normal volunteers, in whom apoE was distributed between very low density lipoproteins (VLDL) and HDL. Consequently, the mean apoE content of HDL in abetalipoproteinemia (44.8 ;g/ml) was more than twice that found in the normal volunteers (20.3 
gg/ml).
ApoE-rich and apoE-poor subfractions of HDL2 were isolated by heparin-agarose affinity chromatography. ApoE comprised a mean of 81% of the protein mass of the apoE-rich subfraction. Compared with the apoE-poor subfraction, the apoE-rich HDL2 was of larger mean particle diameter (141±7 vs. 115±15 A) and had a higher ratio of total cholesterol/protein (1.01±0.11 vs. 0.63±0.14).
Plasma and HDL fractions from three patients were studied with respect to their ability to compete with 1251-LDL in specific binding to receptors on cultured human fibroblasts. The binding activity of plasma from patients (per milligram of protein) was about half that of plasma from normal volunteers. All binding activity in the patients' plasma was found to reside in the HDL fraction. The binding activity of the patients' HDL (on a total protein basis) was intermediate between that of normal HDL and normal LDL. However, the large differences in binding between patients' HDL and normal HDL entirely disappeared when data were expressed in terms of the apoE content of these lipoproteins. This suggested that the binding activity was restricted to that subfraction of HDL particles that contain apoE. These apoE-rich HDL particles had calculated binding potencies per milligram of protein 10-25 times that of normal LDL. Direct binding studies using '25I-apoE-rich HDL2 and 125I-apoE-poor HDL2, confirmed the suggestion that binding is restricted to the subfraction of HDL particles containing apoE. The apoE-rich HDL2 were found to be very potent inhibitors of 3-hydroxy-3-methyl-glutaryl coenzyme A reductase activity in cultured fibroblasts, providing direct evidence of the ability of these lipoproteins to regulate cholesterol metabolism.
On the basis of binding potencies of apoE-rich HDL, apoE concentrations, and the composition of apoE-rich HDL, it could be calculated that apoE-rich HDL in abetalipoproteinemia have a capacity to deliver cholesterol to tissues via the LDL receptor pathway equivalent to an LDL concentration of 50-150 mg/dl of cholesterol. Thus, these apoE-rich lipoproteins are capable of producing the suppression of cholesterol synthesis and LDL receptor activity previously observed in abetalipoproteinemia.
retinal degeneration, and acanthocytosis. The biochemical hallmark of this disease is complete absence of apolipoprotein B (apoB)' which leads to an absence of all apoB-containing lipoproteins, namely, chylomicrons, very low density lipoproteins (VLDL), and low density lipoproteins (LDL) (1) .
Brown and Goldstein (2) have established a major role for LDL, which contains apoB as its sole protein component, in the feedback regulation of cholesterol biosynthesis via the LDL receptor pathway. Thus, it had been predicted that in abetalipoproteinemia the LDL receptor pathway would be completely derepressed (3) (4) (5) (6) . Such derepression would be evidenced by rapid rates of cholesterol biosynthesis, high concentrations of LDL receptors on cell surfaces, high levels of 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG CoA) reductase, and low levels of acylcoenzyme A acyltransferase (ACAT). However, several laboratories have presented data to indicate that the LDL receptor pathway is not derepressed and that total endogenous cholesterol synthesis is not excessive in abetalipoproteinemia (3) (4) (5) (6) (7) .
This report describes an attempt to resolve the apparent paradox of a repressed LDL receptor pathway in the absence of apoB-containing lipoproteins in abetalipoproteinemia. Because of the considerable evidence that apoE can interact with the same cell surface receptor as LDL (8) (9) (10) (11) Some of the findings presented here have previously appeared in abstract form (12) .
METHODS

Subjects
Nine patients with abetalipoproteinemia were studied ( Table I ). All had acanthocytosis, malabsorption, and other typical clinical findings of abetalipoproteinemia. They ranged in age from 1 to 30 yr. Plasma cholesterol and triglyceride levels averaged (±SD) 32±8 mg/dl and 7±3 mg/dl, respectively. No apoB was detectable by radioimmunoassay (RIA) in the plasma of any of the nine patients. The patients' parents had normal plasma cholesterol and triglyceride concentrations, excluding the possibility that some of the patients may have had homozygous hypobetalipoproteinemia rather than abetalipoproteinemia (1). The extremely low 'Abbreviations used in this paper: apoA-I, apoA-II, apoB, apoE, apolipoprotein A-I, A-II, B, and E, respectively; HMG CoA reductase, 3-hydroxy-3-methyl-glutaryl coenzyme A reductase. plasma triglyceride levels and the complete absence of immunoreactive apoB excluded normotriglyceridemic abetalipoproteinemia (13) . The normnal volunteers comprised 50 persons who were selected without prior knowledge of their plasma lipid levels.
They were healthy at the timne of sampling, and they ranged in age from 22 to 62 yr.
RIA of apolipoproteins A-I, A-II, and E
The procedure for double-antibody RIA of apoE has been described in detail (14) . In brief, standards or unknowns were preincubated overnight in 50 mM Na phosphate, 100 mM NaCl, 0.02% Na azide, 50 mM Na decyl sulfate, pH 7.4. The assay was performed in the presence of a final concentration of 5 mM Na decyl sulfate. The within assay coefficient of variation was 9% and the coefficient of variation for systematic between assay variability was 3%.
ApoA-I and apoA-II RIA were performed similarly, except that specific antisera for apoA-I or apoA-II replaced the antiserum for apoE, and radioiodinated apoA-I or apoA-II replaced radioiodinated apoE. Within and between assay coefficients of variation were 10.6 and 9.0% for apoA-I, and 5.0 and 4.4% for apoA-II.
Fractionation of plasma lipoproteins
Agarose column chromatography. Whole plasma (1-2 ml) was applied to a 1.2 X 100-cm column of 6% agarose (Bio-Gel A5M, Bio-Rad Laboratories, Richmond, CA) and was eluted with a solution of 0.2 M NaCl, 1 Heparin-agarose affinity chromatography. Heparin-agarose affinity chromatography was used to fractionate the HDL,2 (d < 1. 125 g/ml lipoproteins) from three patients wvith abetalipoproteinemia. For these studies, in which lipoprotein composition was measured, Na p-chloromercuriphenylsulfonate (2 mM) was added to the bloodl imnmediately after venipunctuire to inhibit the enzvme lecithini cholesterol acvitransferase. These samples were niever frozen. Hepariin-agarose affinity chromatography of HDI,2 was performed in a column containing 10 ml of Sepharose CL-4B to which was bound -100 mg of heparin (Fisher Scientific Co., Pittsburgh, PA) (14) . Lipoproteins were applied to the coluimn in a solution of 5 mM Na phosphate, 0.02% Na azide, pil 7.4. The column was washed with 100 ml of the same buffer, and apoE-rich lipoproteins were then eltted with a soluition of 5 mNM Na phosphate, 500 mM NaCl, 0.02% Na azide, pH 7.4.
Studies of binding to LDL receptors
The ability of plasma and lipoprotein fractions to conmpete with 1251-LDL in binding to fibroblasts was deterninie(d as previously described (15, 16) . Normal human skin fibroblasts were grown as monolayers in tissue culture plates (15 Direct binding of radioiodinated apoE-rich and apol-4-poor HDL2 was assessed at 37°C (16) . ApoE-rich and apoE-poor subfractions of HDL2 were isolated bv heparin-agarose affinity chromatography as described above. Ali(luots of these subfractions were then radioiodinated by a modification of the iodine monochloride method of McFarlane (17, 18) .
After incubation of the cells with '251-apoE-rich or 1251-apoEpoor HDL,2 at 37°C for 5 h, the cells were cooled to 4°C' and the medium removed from each monolayer. The cell monolayers were extensively washed, and '251-lipoprotein cell surface binding was determined by measuring the radioactivity released from the cells by dextran sulfate.
HMG CoA reductase activity
To determine the ability of apoE-rich and apoE-poor HDL,2 from patients with abetalipoproteinemia to regulate the activity of HMG CoA reductase in cultured human fibroblasts, several concentrations of these lipoproteins or of normal LDL were incubated with cultured human fibroblasts for 8 h at 37°C. The medium was then removed and the monolayers were washed once with iced 0. 15 (14) . The gels were stained by the method of Weber and Osborne (20) .
Protein was mleasured by the method of Lowry et al. (21), usinig bovine serum albumin as standar(l. 'I'otal cholesterol in extracts of agarose columin fractioins and in extracts of lipoprotein fractions was measlire(l by the metho(Iof Chiamori and hlenry (22) . Free and esterified cholesterol in apoErich and apoE-poor subfractionus of IIL,2 were measured by gas-liquid chromatography; triglyceride in subfractions was measured by (quantitative thin-layer chiromiatograpthy; phospholipid in subfractions was measured by the method of Bartlett (23) . 'I'he total cholesterol and triglyceride concentrations in plasmia were meiasured using Techiicomn AA-1 nethodology (Technicorn Instruments Corp., Tarrytown, NY) (24, 25) .
RESU LTS
Plasma apoF concentration. The conceiitrationis of apoE in the plasma of the nine patientts with abetali-poproteinemia are given in Table II . The mean±SD apoE concentration of 44.8±8.2 ,ug/ml was significantly greater than the mean±SD of 36.3±11.1 ,ug/ml for a group of 50 normal volunteers (P < 0.025). However, the distribution of plasma total apoE levels in the two groups did overlap considerably; seven of the nine patients had values below the 90th percentile of the normals' distribution (50 ,ug/ml), and 20% of the normals had values exceeding the mean for the patients with abetalipoproteinemia. The three adult patients (No. 1-3) had similar plasma apoE levels to those of the six children with abetalipoproteinemia. Therefore, the single adult control group can be used to show that total plasma apoE concentrations in patients with abetalipoproteinemia are not subnormal.
Distribution of apoE among lipoproteins. Whole plasma from each of seven different patients with abetalipoproteinemia was fractionated by 6% agarose column chromatography yielding a single symmetrical peak of apoE immunoreactivity (Fig. 1, lower panel) . This slightly preceded the single peak of cholesterol in the column eluate and was located where very large particles of normal HDL elute from this same column. This pattern was in sharp contrast to that seen in plasma samples from 30 normal volunteers (Fig. 1 , upper panel) in which two major peaks of apoE immunoreactivity were invariably apparent: a first peak corresponded to VLDL and a second peak corresponded in elution volume to large HDL particles. The peaks of apoE and cholesterol in patients' plasma eluted slightly earlier than the HDL peaks of apoE and cholesterol in normal plasma; this indicated a somewhat larger mean particle size of the lipoproteins in the corresponding fractions from patients with abetalipoproteinemia. In fresh plasma from normal volunteers or from patients with abetalipoproteinemia, all apoE eluted from the column associated with lipoproteins.
Ultracentrifugation demonstrated a lipoprotein distribution of apoE analogous to that seen with column chromatography (Table II) . A mean of 69.3% of plasma apoE was found in the 1.063-1.125 g/ml density range in abetalipoproteinemia, compared with 23.9% in normal volunteers. Even more striking was the finding that only 5.6% of plasma apoE was found in the d < 1.063 g/ml density range; this compared with 38 .4% in this combined VLDL-LDL density range in normal volunteers. It was also of interest that the portion of apoE found in the d > 1.21 g/ml fraction after ultracentrifugation was much smaller in the patients with abetalipoproteinemia (7.6±4.2%) than in the normal volunteers (27.3±6.0%) (P < 0.001).
The observation that in abetalipoproteinemia plasma apoE is localized to a subfraction of HDL is strengthened by the qualitative agreement of two fundamentally different techniques of fractionation, gel filtration and preparative ultracentrifugation. Since all of the apoE in the plasma of these patients was associated or this patient, the sample centrifuged at 1.063 g/ml was lost. Distribution 1.063 g/ml was assumed to be the same as the mean distribution for the other five patients in whom lipoprotein density distributions were measured. The reported SD for d < 1.063 g/ml and for d = 1.063-1.125 g/ml exclude this patient. I n = 50 for plasma apoE concentration; n = 9 for lipoprotein density distribution. ELUTION VOLUME (ml) FIGURE 1 Agarose column chromatography of plasma.
Plasma from a normal volunteer (above) and from patient 2 (below) were applied to a 1.0 X 100-cm column of 6% agarose and were eluted with 0. Preparation and characterization of apoE-rich HDL2. ApoE-rich HDL2 and apoE-poor HDL2 were separated from each other by heparin-agarose affinity chromatography of the d < 1.125 g/ml fraction of plasma from patients 2, 3, 4, and 6. SDS gels of the two fractions of HDL2 obtained from patient 2 are shown in Fig. 2 . The fraction retained by the column and eluted with 0.5 M NaCl (gels 1 and 3) is seen to be truly rich in apoE. The fraction not retained by the column (gels 2 and 4) is seen to contain apoA-I as its major apoprotein. Total recovery of immunoassayable apoE from plasma through the heparin affinity chromatography step averaged 59%. The 41% total loss of apoE occurred as follows: 5% in ultracentrifugation, 12% in dialysis, and 24% in heparin-agarose affinity chromatography.
The results of RIA of the two fractions for apoA-I, apo-II, and apoE are shown in Table I1I . ApoE accounted for a mean of 79.4% of the protein mass of the apoE-rich fractions, while apoA-I accounted for a mean of 76.2% of the protein mass of the apoE-poor fractions.
The percentage of apoE that might be covalently bound to apoA-II in an apoE-apoA-II complex was estimated by two different methods (Table IV) . Method 1 assumed that all of the apoA-II present in the apoErich HDL2 was involved in an apoE-apoA-II complex. The concentration of apoE present in the apoE-apoA-II complex was then calculated as the concentration of the apoE that could be bound by the measured amount of apoA-II, i.e., molar concentration of apoA-II as monomer per molar concentration of apoE. Method 2 for estimating the fraction of apoE in the apoE-apoA-II complex was densitometric scanning of stained SDS polyacrylamide gels of the two fractions. 45 ,500-and the 67,100-dalton bands disappear with a concurrent increase in the relative intensity of the apoE band on treatment of the samples with p-mercaptoethanol (Fig. 2, gel 1) , these two bands are felt to represent apoE-apoA-II and apoE-apoE disulfide dimers, respectively. Their apparent molecular mass is consistent with this interpretation. Lower molecular mass proteins are poorly visualized in the 6% SDS gel system we used; this accounts for the absence of a visible band of apoA-II monomer in gel 1. Estimates of the percent of apoE in the apoE-apoA-II complex by method 1 and by method 2 suggest that about one-third of apoE is bound covalently to apoA- II. Method 2 further suggested that a somewhat smaller fraction of plasma apoE was present in an apoE-apoE disulfide dimer (30% for patient 2, 27% for patient 3). Thus, both methods agree that only a limited amount of apoE may be present in an apoE-apoA-II complex. The apoE-rich and apoE-poor fractions of HDL2 from patients 2, 3, and 6 were analyzed by negativestain electron microscopy (Fig. 3) . The apoE-rich HDL2 were in each case of larger mean particle diameter (141±7 A) than the apoE-poor HDL2 (115±15 A). Both fractions contained a predominant population of spherical or nearly spherical particles. The apoErich HDL2 demonstrated a tendency to aggregate, which resulted in a packing artifact of apparently square-shaped particles. This phenomenon was independent of the temperature of fixation, being evident when samples were fixed at room temperature or at 45°C, i.e., below or above the cholesteryl ester transition temperature. Square-shaped lipoproteins were, however, not seen in very dilute sarnples where only free standing particles were present.
The total cholesterol/protein ratio of apoE-rich HDL2 (1.01±0.11) was higher than that of apoE-poor HDL2 (0.63±0.14). Percent distribution of the lipid components in apoE-rich HDL2 was 23% cholesterol, 32% cholesteryl ester, and 45% phospholipid. In apoEpoor HDL2 it was 21% cholesterol, 44% cholesteryl ester, and 35% phospholipid. The ability of lipoproteins to compete with '251-LDL in binding to fibroblasts is illustrated in Fig. 5 . HDL2 (d = 1.063-1.125 g/ml) from patient 8 had a binding potency intermediate between that of normal HDL2 and normal LDL (d = 1.019-1.050 g/ml) when concentrations were expressed as total protein in the lipoprotein fractions (Fig. 5, panel A) . HDL from patients 6 and 7 had even greater potency relative to LDL or normal HDL when the data were expressed in this manner. However, the difference between HDL from patient 8 and HDL from a normal volunteer disappeared when the lipoprotein concentrations were expressed as the amount of the apoE present (Fig. 5,  panel B) . Studies of the lipoproteins of patients 6 and 7 yielded similar results. These data support the hypothesis that all of the LDL receptor binding activity of HDL resides in the small subset of HDL particles containing apoE. (20) is plotted on another scale on the abscissa. In comparing the relative binding activities of apoE-rich HDL and normal LDL on this plot, it can be seen that any given concentration of apoE-rich HDL2 from patient 8 had, on a protein basis, equivalent binding activity to 10 times that concentration of normal LDL. Thus, apoE-rich HDL2 from patient 8 had 10 times the potency of normal LDL for binding to LDL receptors of cultured human fibroblasts. ApoE-rich HDL2 from patients 6 and 7 had measured LDL receptor binding potencies of 25 and 11 times that of normal LDL. It is possible, since the apoE-apoA-II dimer does not interact with LDL receptors, that patient-to-patient variation in receptor binding potency of apoE-rich HDL may be due to variation in the fraction of apoE bound to apoA-II. The experiments described above demonstrated the ability of the patients' HDL2 to compete with normal 1251-LDL for binding sites on cultured human fibroblasts; those experiments suggested that it was the apoE-rich subfraction of the patients' HDL2 that contained the LDL receptor binding activity. This suggestion was confirmed in another series of experiments demonstrating specific binding of apoE-rich HDL2 to fibroblasts (Fig. 6) . ApoE-rich and apoE-poor subfractions of HDL2 were isolated from patients 2 and 4. Radioiodinated aliquots of these HDL2 subfractions were then tested for their ability to bind to fibroblasts. At any particular lipoprotein concentration, binding of apoE-rich HDL2 was much greater than was that of apoE-poor HDL2. The binding of apoE-rich HDL2 could be substantially inhibited (86% inhibition) by including 400 ,ug/ml of normal LDL in the incubation medium, further indicating that this binding involved the LDL receptor. In contrast, 400 jig/ml of LDL produced only 5% inhibition of the binding of apoE-poor HDL2 to fibroblasts.
Apolipoprotein E in Abetalipoproteinemia
An additional series of experiments was performed to demonstrate that the apoE-rich HDL2 of abetalipoproteinemia were not only capable of binding to LDL receptors, but could also effectively suppress HMG CoA reductase activity. ApoE-rich and apoEpoor HDL2 from subjects 2 and 4 were used in these experiments. The data from subject 4 are presented in Fig. 7 . The regulatory activity of apoE-rich HDL2 per microgram of lipoprotein protein was -3.5 times that of normal LDL and -20 times that of the apoEpoor fraction of HDL2 from the same patient. Since apoE accounted for 3.5% of the protein of the apoEpoor fraction and 73.5% of the protein in the apoErich fraction from this patient, the difference in reductase-suppressing activity of the two fractions is entirely consistent with the concept that all of that activity resides in the apoE-containing lipoproteins. Similar results were obtained in experiments with the apoE-rich and apoE-poor subfractions of HDL2 from patient 2. There was also a 20-30-fold difference in reductase regulating activity of the two fractions, corresponding to a 20-30-fold difference in the apoE contents of the two subfractions and strongly supporting the concept that the small amount of reductase-regulating activity in the apoE-poor fraction results entirely from small amounts of contamination (3.5%) with apoE-containing HDL2.
DISCUSSION
In previous studies of the abnormal lipoproteins of abetalipoproteinemia, Scanu et al. (26) (28, 29) : the fractions richl irn apoE-contained particles of larger mean diameter and higher cholesterol/protein ratio than did those poor in apoE. As had b)een inoted when 1-H1)12 was isolated by zonal ultracenitrifugation (30) , we found that the HDI-2 of abetalipoproteinemia was of larger mean particle size thain the HDL2 of normal volunteers. We found this to be the case for both sub)fractions of HDL2 as well as for that entire lipoprotein class when our data on particle diameter for abetalipoproteinemia (apoE-rich IIDDL2 141 A, apoEpoor HDL2 1 15 A) were compared withl the normative (lata of Weisgraber and Mahley (28) (apoE-rich HDL2, 122 A, apoE-poor HDL2 95 A). Consistent with this, we found higher cholesterol/protein ratios in apoErich HDL2 from the patients than had been reported by Weisgraber and Mahley (28) or by Marcel et al. (29) for the corresponding subfractions of normal HDL2. The apoE-rich HDL2 particles in abetalipoproteinemia have -1.5 times the volume of apoE-rich HDL2 in normals. Thus, cellular cholesterol delivery per bound apoE-rich HDL2 particle in abetalipoproteinemia can be expected to be 1.5 times that in normals.
Because of the report that the apoE-apoA-11 disulfide dimer does not interact with LDL receptors (31) , it was of interest that in the apoE-rich HDL.2 about one-third of apoE was in monomeric form, about onethird vas in an apoE-ApoA-II dimer, and about onethird was in an apoE-apoE dimer. Our estimates of the amount of apoE-apoA-II dimer present were made with tvo fundamentally different methods that gave similar results. Method 1, based on the amount of immunoassayable apoA-II and apoE present in apoE-rich HIDL2 should theoretically yield an upper bound for the amount of apoE-apoA-II dimer present. Method 2 was based on densitometric scanning of stained SDS polyacrylamide gels after electrophoresis of the proteins of apoE-rich HDL.2. Since the sulfhydryl-binding reagent p-chloromercuriphenylsulfonate had been added to these samples immediately after venipunc-ture, it is to be expected that there was no in vitro formation of apoE-apoA-I1 dimer or of apoE-apoE dimer and that the estimate truly reflected the forms of circulating apoE. Both methods agree that only a limited portion of apoE may be present in the apoEapoA-II dimer in the three patients studied.
In the study of the regulation of cholesterol synthesis in nonhepatic tissues, the case of abetalipoproteinemia has been seen as potentially instrtuctive. It was initially expected that the primacy of the LDL in this regulation would be evidenced by the finding of elevated levels of HNIG CoA reductase activity, LDL receptor activity, and cholesterol synthesis in abetalipoproteinemia (3-6). However, after an initial report that plasma from a patient with abetalipoproteinemnia did not suppress HMG CoA reductase activity in cultured human fibroblasts (32) 
